Dennis P A Wander

7PUBLICATIONS
18CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsBiologically active moleculesGlycoconjugates
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 01, 2024
Novel N,N-Dimethyl-idarubicin Analogues Are Effective Cytotoxic Agents for ABCB1-Overexpressing, Doxorubicin-Resistant Cells.

Merle A van Gelder, Yufeng Li, Dennis P A Wander

|Aug 10, 2023
Re-Exploring the Anthracycline Chemical Space for Better Anti-Cancer Compounds.

Merle A van Gelder, Sabina Y van der Zanden, Merijn B L Vriends

|Mar 30, 2021
Synthetic (N,N-Dimethyl)doxorubicin Glycosyl Diastereomers to Dissect Modes of Action of Anthracycline Anticancer Drugs.

Dennis P A Wander, Sabina Y van der Zanden, Merijn B L Vriends

|Oct 16, 2020
Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents.

Dennis P A Wander, Sabina Y van der Zanden, Gijsbert A van der Marel

|Jun 20, 2020
Uncoupling DNA damage from chromatin damage to detoxify doxorubicin.

Xiaohang Qiao, Sabina Y van der Zanden, Dennis P A Wander

|Apr 11, 2020
Immunoproteasome Inhibitor-Doxorubicin Conjugates Target Multiple Myeloma Cells and Release Doxorubicin upon Low-Dose Photon Irradiation.

Elmer Maurits, Michel J van de Graaff, Santina Maiorana

Pageof 2